Neuropeptide Y receptors are a class of G-protein coupled receptors which are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide.[1] These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.[2][3][4][5][6][7]
Activated neuropeptide receptors release the Gi subunit from the heterotrimeric G protein complex. The Gi subunit in turn inhibits the production of the second messenger cAMP from ATP.
There are five known mammalian neuropeptide Y receptors designated Y1 through Y5.[8] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders.[9][10][11]
Antagonists[edit]
References[edit]
- ^ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID 9549761.
- ^ Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID 15337373.
- ^ Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID 16738800.
- ^ Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry 7 (17): 1645–59. doi:10.2174/156802607782341037. PMID 17979774.
- ^ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery 1 (3): 315–24. doi:10.2174/157488906778773689. PMID 18221213.
- ^ Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry 7 (17): 1710–20. doi:10.2174/156802607782340966. PMID 17979780.
- ^ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. doi:10.1016/j.nut.2008.06.025. PMID 18725086.
- ^ Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides 38 (4): 141–51. doi:10.1016/j.npep.2004.06.002. PMID 15337367.
- ^ Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews 28 (6): 664–84. doi:10.1210/er.2007-0003. PMID 17785427.
- ^ MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID 17979781.
- ^ Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry 7 (17): 1734–42. doi:10.2174/156802607782340957. PMID 17979782.
External links[edit]
|
|
|
| CGRP |
|
|
| Cholecystokinin |
|
|
| CRH |
|
|
| Galanin |
|
|
| Ghrelin/GHS |
|
|
| MCH |
|
|
| Melanocortin |
|
|
| Neuropeptide FF |
|
|
| Neuropeptide S |
|
|
| Neuropeptide Y |
|
|
| Neurotensin |
|
|
| Opioid |
|
|
| Orexin |
|
|
| Oxytocin |
|
|
| Tachykinin |
|
|
- Antagonists: Aprepitant
- Befetupitant
- Burapitant
- Casopitant
- CI-1021
- CP-96,345
- CP-99,994
- CP-122,721
- Dapitant
- Ezlopitant
- Figopitant
- FK-888
- Fosaprepitant
- Fosnetupitant
- GR-203,040
- GW-597,599
- HSP-117
- L-733,060
- L-741,671
- L-743,310
- L-758,298
- Lanepitant
- LY-306,740
- Maropitant
- Netupitant
- NKP-608
- Nolpitantium besilate
- Orvepitant
- Rolapitant
- RP-67,580
- SDZ NKT 343
- Serlopitant
- Telmapitant
- Tradipitant
- Vestipitant
- Vofopitant
|
|
|
|
|
|
|
|
|
|
|
| Vasopressin |
|
|
|
|
|
